DelveInsight’s “Progressive Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Progressive Pulmonary Fibrosis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Progressive Pulmonary Fibrosis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Progressive Pulmonary Fibrosis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Progressive Pulmonary Fibrosis: An Overview
Progressive pulmonary fibrosis (PPF), also referred to as progressive fibrosing interstitial lung disease (PF-ILD), defines the continuing worsening of any preexisting ILD of known or unknown etiology despite appropriate treatment.
Interstitial lung disease is believed to be caused by long-term exposure to hazardous materials, such as asbestos or coal dust, or it can be caused by an auto-immune disease such as rheumatoid arthritis. Once lung scarring occurs, it is generally irreversible.
PPFs are composed of idiopathic interstitial pneumonia such as non-specific interstitial pneumonia and unclassifiable interstitial pneumonia and inhalation lung diseases such as chronic hypersensitivity pneumonia and connective tissue disease-associated ILD such as rheumatoid arthritis-related ILD and SSc-related ILD and sarcoidosis and so on. Many interstitial lung diseases (ILDs) are characterized by chronic progressive fibrosis.
Treatment for ILDs varies depending on the type of ILD diagnosed and the severity. Lung damage from ILDs is often irreversible and progressive, so treatment normally centers on relieving symptoms, improving quality of life and slowing the disease’s progression. Medications, such as corticosteroids, can be used to decrease inflammation in the lungs. Nintedanib (Ofev) is the only approved drug in the PPF treatment landscape.
Progressive Pulmonary Fibrosis Market Key Facts
The United States accounts for the highest market size of Progressive pulmonary fibrosis (PPF) approximately 77% of the total market size in 7MM in 2021, in comparison to the other major markets i.e., EU5 countries (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
Among the EU5 countries, Germany had the highest market size with USD 37 million in 2021, while Spain had the lowest market size of Progressive pulmonary fibrosis (PPF) with USD 28 million in 2021.
The market size for Progressive pulmonary fibrosis (PPF) in Japan was estimated to be USD 43 Million in 2021, which accounts for 5% of the total 7MM market.
With the expected launch of upcoming therapies, such as BI 1015550 the total market size of Progressive pulmonary fibrosis (PPF) is expected to show change in the upcoming years.
In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Progressive pulmonary fibrosis (PPF) in the 7MM was 127,754 in 2021.
The highest total diagnosed prevalent cases of Progressive pulmonary fibrosis (PPF) were accounted by the US in 2021 (71,657 cases), which are expected to show a rise in the future.
Among the European countries, Germany had the highest diagnosed prevalent cases of PPF with 11,115 cases, followed by the United Kingdom, which had a prevalent population of 9,872 in 2021. On the other hand, Spain had the lowest prevalent population (6,401 cases).
Japan had 10,296 total diagnosed prevalent cases of Progressive pulmonary fibrosis (PPF) in 2021, accounting for approximately 8% of the 7MM.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Progressive Pulmonary Fibrosis pipeline therapies. It also thoroughly assesses the Progressive Pulmonary Fibrosis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Progressive Pulmonary Fibrosis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Progressive Pulmonary Fibrosis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Progressive Pulmonary Fibrosis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Progressive Pulmonary Fibrosis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Progressive Pulmonary Fibrosis Epidemiology, Segmented as –
Total Prevalent Cases of Interstitial Lung Disease (ILD)
Total Diagnosed Prevalent Cases of Interstitial Lung Disease (ILD)
Type-specific Diagnosed Prevalent Cases of Interstitial Lung Disease (ILD)
Total Diagnosed Prevalent Cases of Progressive pulmonary fibrosis (PPF)
Progressive Pulmonary Fibrosis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Progressive Pulmonary Fibrosis market or expected to be launched during the study period. The analysis covers the Progressive Pulmonary Fibrosis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Progressive Pulmonary Fibrosis drugs based on their sale and market share.
The report also covers the Progressive Pulmonary Fibrosis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Progressive Pulmonary Fibrosis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Progressive Pulmonary Fibrosis Market Will Evolve and Grow by 2032 @
Progressive Pulmonary Fibrosis Companies Actively Working in the Therapeutics Market Include
Hoffmann-La Roche Ltd.
Pliant Therapeutics, Inc.
Vicore Pharma AB.
And Many Others
Emerging and Marketed Progressive Pulmonary Fibrosis Therapies Covered in the Report Include:
BI 1015550: Boehringer Ingelheim
Ofev (Nintedanib): Boehringer Ingelheim Pharmaceuticals, Inc.
And Many More
The Report Covers an In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Progressive Pulmonary Fibrosis Competitive Intelligence Analysis
4. Progressive Pulmonary Fibrosis Market Overview at a Glance
5. Progressive Pulmonary Fibrosis Disease Background and Overview
6. Progressive Pulmonary Fibrosis Patient Journey
7. Progressive Pulmonary Fibrosis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Progressive Pulmonary Fibrosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Progressive Pulmonary Fibrosis Unmet Needs
10. Key Endpoints of Progressive Pulmonary Fibrosis Treatment
11. Progressive Pulmonary Fibrosis Marketed Therapies
12. Progressive Pulmonary Fibrosis Emerging Drugs and Latest Therapeutic Advances
13. Progressive Pulmonary Fibrosis Seven Major Market Analysis
14. Attribute Analysis
15. Progressive Pulmonary Fibrosis Market Outlook (In US, EU5, and Japan)
16. Progressive Pulmonary Fibrosis Companies Active in the Market
17. Progressive Pulmonary Fibrosis Access and Reimbursement Overview
18. KOL Views on the Progressive Pulmonary Fibrosis Market
19. Progressive Pulmonary Fibrosis Market Drivers
20. Progressive Pulmonary Fibrosis Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Hairy Cell Leukemia (HCL) Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Hairy Cell Leukemia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Hairy Cell Leukemia market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States